ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy

Trial Profile

ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Apalutamide (Primary) ; Bicalutamide
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ATLAS
  • Sponsors Aragon Pharmaceuticals; Janssen-Cilag
  • Most Recent Events

    • 07 Mar 2017 Planned End Date changed from 1 Oct 2026 to 6 Oct 2026.
    • 07 Mar 2017 Planned primary completion date changed from 1 Dec 2022 to 30 Dec 2022.
    • 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top